Sotac Pharma.

Which are the latest news on Sotac Pharma.?

Why is Sotac Pharmaceuticals Ltd falling/rising?

As of 05-Sep, Sotac Pharmaceuticals Ltd's stock price is at 90.05, unchanged from the previous session, but has declined 26.85% year-to-date. The stock shows bearish trends with reduced investor interest and weak long-term fundamentals, contributing to its downward pressure.

As of 05-Sep, Sotac Pharmaceuticals Ltd's stock price is currently at 90.05, showing no change from the previous trading session. The stock has experienced a significant decline over the year-to-date, with a drop of 26.85%, compared to a lesser decline of 8.54% in the benchmark Sensex. Over the past month, the stock has decreased by 5.11%, while the Sensex has only fallen by 2.91%. <BR><BR>The stock is currently trading 4.5% away from its 52-week low, indicating it is close to a significant low point. Additionally, Sotac Pharmaceuticals is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically suggests a bearish trend. Investor participation has also declined, with delivery volume falling by 28.57% compared to the 5-day average, reflecting reduced interest from investors.<BR><BR>Despite having a relatively attractive valuation with a return on capital employed (ROCE) of 5.4 and a low enterprise value to capital employed ratio of 1.4, the company's long-term fundamentals appear weak. The company has not declared results in the last six months, and its net sales growth over the past five years has been modest at an annual rate of 9.30%. Furthermore, profits have fallen by 28% over the past year, contributing to a negative sentiment around the stock.<BR><BR>Overall, the combination of poor performance metrics, declining investor interest, and weak long-term growth prospects are contributing to the downward pressure on Sotac Pharmaceuticals Ltd's stock price.

Who are in the management team of Sotac Pharma.?

The management team of Sotac Pharma includes Sharadkumar Patel (Chairman & Managing Director), Dineshkumar Gelot (Whole-time Director), Vishalkumar Patel and Chetankumar Patel (Executive Directors), and independent directors Ms. Nidhiben Patel, Hetal Shah, and Heena Patel. They oversee the company's strategic direction and management.

The management team of Sotac Pharma includes the following individuals:<BR><BR>1. **Sharadkumar Dashrathbhai Patel** - Chairman & Managing Director<BR>2. **Dineshkumar Babulal Gelot** - Whole-time Director<BR>3. **Vishalkumar Devrajbhai Patel** - Executive Director<BR>4. **Chetankumar Bachubhai Patel** - Executive Director<BR>5. **Ms. Nidhiben Patel** - Independent Non-Executive Director<BR>6. **Hetal Umangbhai Shah** - Independent Non-Executive Director<BR>7. **Heena Viral Patel** - Independent Non-Executive Director<BR><BR>This team is responsible for the strategic direction and management of the company.

What does Sotac Pharma. do?

Sotac Pharmaceuticals Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, established in 2015, with recent net sales of 25 Cr and a net profit of 1 Cr as of June 2024. Key metrics include a P/E ratio of 21.00 and a market cap of INR 100 Cr.

Overview:<BR>Sotac Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Sotac Pharmaceuticals was originally established as a Partnership Firm in 2015 and was converted into a Private Limited Company later that same year. The latest quarterly results reported net sales and net profit for June 2024.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 25 Cr (Quarterly Results - Jun 2024) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Jun 2024) <BR>Market-cap value: INR 100 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 21.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.11% <BR>Debt Equity: 0.62 <BR>Return on Equity: 8.11% <BR>Price to Book: 1.69 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Sotac Pharma.?

Sotac Pharma's peers include Onyx Biotec, Denis Chem Lab, Veerhealth Care, and others. Management risk varies from excellent at Denis Chem Lab to below average at Sotac Pharma, with growth and capital structure ratings also differing among peers.

Peers: The peers of Sotac Pharma are Onyx Biotec, Denis Chem Lab, Veerhealth Care, Mercury Labs, Concord Drugs, Asston Pharmaceu, Godavari Drugs, Amwill Health, and Tyche Industries.<BR><BR>Quality Snapshot: Excellent management risk is observed at Denis Chem Lab and Amwill Health, while Average management risk is found at Onyx Biotec, Asston Pharmaceu, Godavari Drugs, and Tyche Industries, and the rest. Below Average management risk is noted at Sotac Pharma, Veerhealth Care, and Concord Drugs. Growth is classified as Good at Veerhealth Care, Average at Sotac Pharma and Amwill Health, and Below Average at Onyx Biotec, Denis Chem Lab, Mercury Labs, Asston Pharmaceu, Godavari Drugs, and Tyche Industries, and the rest. Capital Structure is Excellent at Denis Chem Lab and Mercury Labs, Average at Sotac Pharma, Onyx Biotec, Asston Pharmaceu, and Tyche Industries, and Below Average at Veerhealth Care, Concord Drugs, and Godavari Drugs, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Denis Chem Lab at 0.00%, while the peer with the lowest is Onyx Biotec at -14.58%. Sotac Pharma's 1-year return is not available for comparison. Additionally, all peers have a six-month return of 0.00%, indicating no negative returns in that period.

How big is Sotac Pharma.?

As of 31st August, Sotac Pharmaceuticals Ltd has a market capitalization of 100.00 Cr, with net sales of 104.11 Cr and a net profit of 4.64 Cr reported in the latest four quarters. The company has shareholder's funds of 53.25 Cr and total assets of 123.03 Cr as of March 2025.

As of 31st August, Sotac Pharmaceuticals Ltd has a market capitalization of 100.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Sotac Pharmaceuticals reported net sales of 104.11 Cr and a net profit of 4.64 Cr.<BR><BR>As of the latest annual period in March 2025, the company has shareholder's funds amounting to 53.25 Cr and total assets of 123.03 Cr.

Should I buy, sell or hold Sotac Pharmaceuticals Ltd?

How has been the historical performance of Sotac Pharma.?

Sotac Pharma's historical performance shows fluctuating net sales, peaking at 103.83 Cr in March 2024 before declining to 96.99 Cr in March 2025, while profitability improved significantly with profit after tax rising to 9.28 Cr in March 2025 from 3.58 Cr in the previous year. Total assets and liabilities both increased to 123.03 Cr in March 2025, indicating growth in operations despite negative cash flow from operating activities.

Answer:<BR>The historical performance of Sotac Pharma shows a fluctuating trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Sotac Pharma's net sales peaked at 103.83 Cr in March 2024 but declined to 96.99 Cr by March 2025, following a steady increase from 28.60 Cr in March 2020 to 77.48 Cr in March 2023. Total operating income mirrored this trend, reaching 96.99 Cr in March 2025. The company's total expenditure, excluding depreciation, was 83.34 Cr in March 2025, down from 95.32 Cr in March 2024, which contributed to an operating profit of 17.55 Cr in March 2025, a significant increase from 9.00 Cr in the previous year. Profit before tax also rose to 11.12 Cr in March 2025, compared to 3.96 Cr in March 2024, leading to a profit after tax of 9.28 Cr, up from 3.58 Cr. The earnings per share improved to 7.27 in March 2025 from 3.87 in March 2024. On the balance sheet, total assets increased to 123.03 Cr in March 2025, while total liabilities also rose to 123.03 Cr, indicating a growing scale of operations. Cash flow from operating activities remained negative at -4.00 Cr in March 2025, although cash flow from financing activities was positive at 16.00 Cr, reflecting ongoing investments and financing strategies.

Is Sotac Pharma. overvalued or undervalued?

As of October 7, 2025, Sotac Pharma is fairly valued with a PE ratio of 26.26, an EV to EBITDA of 19.97, and a PEG ratio of 0.33, making it attractive compared to peers like Sun Pharma and Divi's Lab, despite a 13.16% decline over the past year.

As of 7 October 2025, the valuation grade for Sotac Pharma has moved from very attractive to attractive. The company is currently fairly valued. Key ratios include a PE ratio of 26.26, an EV to EBITDA of 19.97, and a PEG ratio of 0.33, indicating a relatively low growth expectation compared to its earnings. <BR><BR>In comparison to its peers, Sotac Pharma's PE ratio is lower than Sun Pharma's 34.6 and Divi's Lab's 70.24, which are considered expensive. However, it is higher than Cipla's attractive PE of 22.68 and Dr. Reddy's Labs at 18.37, both of which suggest a more favorable valuation. Despite a recent stock return of 5% over the past week compared to the Sensex's 2.02%, the longer-term performance shows a decline of 13.16% over the past year, reinforcing the notion that the stock is currently fairly valued within its sector.

Who are the top shareholders of the Sotac Pharma.?

The top shareholders of Sotac Pharma include Kiran Baldevbhai Jotania with 13.11%, foreign institutional investors holding 15.12%, and Nav Capital Vcc - Nav Capital Emerging Star Fund as the largest public shareholder at 7.09%. Individual investors own 4.7% of the shares, with no pledged promoter holdings or mutual fund schemes.

The top shareholders of Sotac Pharma include several key players. The majority shareholders are the promoters, with Kiran Baldevbhai Jotania holding the highest stake at 13.11%. Additionally, there are three foreign institutional investors (FIIs) collectively holding 15.12% of the shares. The highest public shareholder is Nav Capital Vcc - Nav Capital Emerging Star Fund, which holds 7.09%. Individual investors account for 4.7% of the company's shares. Notably, there are no pledged promoter holdings or mutual fund schemes involved.

What is the technical trend for Sotac Pharma.?

As of May 30, 2025, Sotac Pharma shows a mildly bullish trend overall, supported by the weekly MACD and moving averages, but caution is advised due to mixed signals from the weekly RSI and OBV.

As of 30 May 2025, the technical trend for Sotac Pharma has changed from sideways to mildly bullish. The weekly MACD indicates a bullish stance, while the daily moving averages also reflect a mildly bullish outlook. However, the weekly RSI is bearish, suggesting some weakness in momentum. The Bollinger Bands on a weekly basis are mildly bullish, but the monthly view is bearish. The KST is bullish on the weekly timeframe, while the OBV shows a mildly bearish trend. Overall, the current technical stance is mildly bullish, but the mixed signals, particularly from the RSI and OBV, indicate caution.

When is the next results date for Sotac Pharma.?

No Upcoming Board Meetings

Has Sotac Pharma. declared dividend?

No Dividend History Available